Murine CD133+CD49flow/+ Cells Derived from ESCs Differentiate into Insulin Producing Cells in vivo
Jesus Ciriza, Christa Caneda, Bryce McLelland and Jennifer O. Manilay
Article Type: Research Article | First Published: December 31, 2014
Pancreatic progenitors have been identified and isolated during embryonic development showing their potential to differentiate into insulin producing cells after transplantation. Subsequently, they have been proposed as an alternative to the treatment of Type I diabetes. However, fetal pancreata represent a limited donor supply and we proposed that ESC-derived pancreatic progenitors are another possible option....
Functionalized Nanoscaffolds to Promote Osteogenic Differentiation in Adipose Derived Human Mesenchymal Stem Cells
Venu Polineni, Chi-Shuo Chen, Wei-Chun Chin and Anand Gadre
Article Type: Research Article | First Published: December 15, 2014
Biocompatible polymers have been successfully implemented to generate nanofibers for bone tissue engineering. This work focused on generating and functionalizing Poly-l-Lactic-coGlycolic Acid (PLGA) nanofiber scaffolds in the range of 700 nm using the electrospinning technique. Our specific objective is to design synthetic biodegradable scaffolds comprising electrospun nanofibers that will not only be osteoconductive but also contain porosity for bone cell ingrowth enhanced with Adipose derived ...
Impact of New Genome Editing Tools on iPS Cell Based Therapies
Jianbo Wu and Radbod Darabi
Article Type: Review Article | First Published: December 14, 2014
Embryonic stem cells (ES cells) have unique differentiation and self- renewal potential which makes them a potential candidate for cell therapy in degenerative disorders. However, the limitation of deriving ES cells from embryos and their immune-incompatibility hinder their clinical applications. Fortunately, by introduction of somatic cell reprogramming technology into induced pluripotent stem cells (iPS cells), the limitations of ES cells have been circumvented. Therefore iPS cells have been c...
Heterogeneity and Diversity of Cancer Stem Cells in Glioblastoma
N. Sumru Bayin and Dimitris G. Placantonakis
Article Type: Editorial | First Published: August 13, 2014
Glioblastoma (GBM) is the most common and deadly primary brain malignancy, with an annual incidence of over 10,000 new cases in the US and a median survival of 14-16 months. The current standard of care includes surgical resection followed by postoperative radiotherapy and treatment with the alkylating agent temozolamide. Sadly, prognosis for GBM patients has increased only incrementally and rather marginally over the past half century. The fact that GBM has lagged behind other solid malignancie...